Medicine
Arixtra 5 mg/0.4 mL injection
Arixtra 5 mg/0.4 mL injection is a prescription medicine containing Fondaparinux for subcutaneous use, marketed by Mylan Institutional, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Fondaparinux
- Brand
- Arixtra
- Strength
- 5 mg/0.4 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 10 syringes of 0.4 mL
- Marketing authorisation holder
- Mylan Institutional
- Manufacturer
- Mylan Institutional
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AX05 Fondaparinux
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 May 2014
- Identifiers
- RxCUI 861356, 861358, 861360 +5DailyMed set ID d3b30c68-cf45-4b46-8ba6-72090f7ba01aNDC 67457-593Application NDA021345
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 syringe, glass in 1 carton / .4 mL in 1 syringe, glass | 67457-593-04 | Mylan Institutional | 19 May 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Fondaparinux 5 mg/0.4 mL injection.
Other strengths and forms of Fondaparinux
Clinical summary
Fondaparinux is a factor Xa inhibitor indicated for prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery, among other approved uses. MedsAcross supplies Fondaparinux for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FondaparinuxFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Fondaparinux Sodium prescribing information (Mylan Institutional) · U.S. National Library of Medicine, DailyMed
- Arixtra: European public assessment report (EPAR) · European Medicines Agency
Need Arixtra 5 mg/0.4 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.